These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 2483776)

  • 1. [Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)].
    Pittrová H; Koza V; Vozobulová V; Cetkovský P; Skopek P; Jungerová J; Cepelák V
    Vnitr Lek; 1989 Dec; 35(12):1177-82. PubMed ID: 2483776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
    Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K
    Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of the treatment of non-Hodgkin's lymphoma with 6 cytostatic drug combination].
    Kotlarek-Haus S; Wołowiec D; Kuliszkiewicz-Janus M; Frydecka I; Urbaniak-Kujda D; Kuliczkowski K
    Przegl Lek; 1989; 46(8):636-40. PubMed ID: 2480621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations.
    Connors JM; Klimo P
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):41-6. PubMed ID: 2456622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive combination chemotherapy (TTL-I protocol) of large cell and immunoblastic lymphomas--long-term observation.
    Koza I; Mardiak J; Bohunický L; Svancárová L; Fuchsberger P; Gyárfás J; Horák I; Spánik S; Sufliarsky J; Thalmeinerová Z
    Neoplasma; 1992; 39(1):43-7. PubMed ID: 1382234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MACOP-B treatment for intermediate and high-grade non-Hodgkin's lymphomas at diagnosis and in relapse.
    Tarella C; Gallo E; Ferrero D; Badoni R; Carlesso N; Caracciolo D; Pileri A
    Haematologica; 1990; 75(2):149-54. PubMed ID: 1694155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of three polychemotherapy programs in non-Hodgkin's lymphomas.
    Konopka L; Pawelski S
    J Chemother; 1989 Jul; 1(4 Suppl):1259-62. PubMed ID: 16312857
    [No Abstract]   [Full Text] [Related]  

  • 11. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified MACOP-B chemotherapy for intermediate and high grade non Hodgkins lymphomas.
    Gopal R; Nair R; Saikia TK; Soman CS; Dinshaw KA; Advani SH
    J Assoc Physicians India; 1994 Oct; 42(10):781-4. PubMed ID: 7533151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Low-grade non-Hodgkin's lymphoma: intensive combined chemotherapy].
    Hattori M; Motomura S; Tomita N; Taguchi J; Tanabe J; Sakai R; Fujisawa S; Fukawa H; Kanamori H; Mouri H; Maruta A; Kodama F; Okubo T
    Rinsho Ketsueki; 1996 Feb; 37(2):101-8. PubMed ID: 8852026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
    Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP
    Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The treatment of large-cell non-Hodgkin's lymphomas with the MACOP-B protocol].
    Montalbán C; Rodríguez García JL; Marcos Robles J; Serrano M; Arechaga S; Perales J; Bellas C
    Med Clin (Barc); 1991 Oct; 97(14):521-5. PubMed ID: 1721672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].
    Gutiérrez J; Osorio G; García H; Vacarezza R; Cao C
    Rev Med Chil; 1991 Sep; 119(9):990-1000. PubMed ID: 1726958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
    Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
    Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Provisional treatment results of intensive combination chemotherapy (m-BACOD) in non-Hodgkin lymphoma of intermediate and high malignancy].
    Knecht H; Streuli RA; Odermatt BF; Rhyner K
    Schweiz Med Wochenschr; 1987 Dec; 117(50):2038-41. PubMed ID: 2448874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
    Zinzani PL; Martelli M; Magagnoli M; Zaja F; Storti S; Pavone E; Lauta VM; De Renzo A; Gobbi M; Bocchia M; Ronconi F; Scaramucci L; Gherlinzoni F; Palombi F; Bendandi M; Stefoni V; Anticoli Borza P; Cellini C; Mandelli F; Tura S
    Haematologica; 1999 Nov; 84(11):996-1001. PubMed ID: 10553159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical outcomes in low grade follicular lymphoma].
    Yamazaki T; Kura Y; Sato Y; Irie T; Kaneita Y; Mochimaru J; Hanai M; Yasukawa K; Sawada U; Horie T
    Rinsho Ketsueki; 1999 Jan; 40(1):1-8. PubMed ID: 10067089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.